Drug news
NICE recommends RoActemra(Roche) for Systemic Idiopathic Juvenile Arthritis
The National Institute for Health and Clinical Excellence (NICE) has published final guidance that recommends RoActemra (tocilizumab)from Roche for the treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) for use in patients aged two and older who have sJIA in whom specific previous treatments have not produced an adequate response subject to Roche making the drug available with a discount as part of a patient access scheme (PAS).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.